Case 3: Managing Poorly Controlled Psoriasis

Experts discuss the final hypothetical patient case involving a 46-year-old man with 12% BSA, high-impact area involvement, and a history of failed adalimumab, topicals, and phototherapy. Experts agree this clearly defines a patient needing systemic therapy, according to major guideline criteria. The challenge is motivating someone disheartened by past treatment burdens.

The shared decision-making conversation focuses on patient lifestyle: needle phobia, travel frequency, and desire to avoid daily disease reminders. Clinicians frame new biologics as superior "technology" compared to older options, emphasizing higher efficacy, safety, and convenience. Goal setting is collaborative and progressive, with scheduled follow-ups at three and six months for "recalibration" if targets aren't met. This reinforces partnership and flexibility, assuring the patient that multiple effective options exist and the goal is sustained, high-level clearance tailored to their life.